机构:[1]Beijing Univ Chinese Med, Sch Life Sci, Beijing 100029, Peoples R China[2]Beizhong Jingyuan Biotechnol Beijing Ltd, Beijing, Peoples R China[3]Beijing Univ Chinese Med, Shenzhen Hosp, Shenzhen 518116, Peoples R China[4]Tangyi Holdings Shenzhen Ltd, Shenzhen, Peoples R China[5]Sun Yat Sen Univ, Coll Life Sci, State Key Lab Biocontrol, Guangdong Prov Key Lab Pharmaceut Funct Genes, Guangzhou 510006, Guangdong, Peoples R China
There is an urgent need for novel therapies to treat end -stage liver disease due to the shortage of available organs. Although cell transplantation holds considerable promise, its availability is limited due to the low engrafted cell mass and lack of unifying cell transplantation strategies. Here, we optimally established human induced pluripotent stem cell -derived functional hepatobiliary organoids (HBOs) based on our previous research and transplanted them into a monkey model via liver subcapsular and submesenteric transplantation routes to assess their potential clinical application. Our study revealed that HBO transplantation could safely and effectively improve hepatoprotection effects by antiapoptotic and antifibrotic agents. In addition, we also discovered that while multiple HBO transplantation pathways may have a shared effector mechanism, their respective treatment approaches have distinct advantages. Transplantation of HBOs could promote the high expression of CTSV in hepatic sinusoid endothelial cells, which might halt the progression of hepatic sinusoidal capillarization and liver fibrosis. Liver subcapsular transplants had stronger pro-CTSV upregulation than HBO submesenteric transplants, which could be attributed to naturally high CTSV expression in HBOs. Interestingly, both transplantation routes of HBOs were targeted the injured liver and triggered a new pattern of ductular reaction to alleviate the degree of liver fibrosis by surrounding the area with CK19-positive labeled cells. These residing, homing and repairing effects might be related to the high expression of MMP family genes. By promoting a unique pattern of ductular reactions, submesenteric HBO transplantation has a more representative antifibrotic impact than liver subcapsular transplantation. Altogether, our data strongly imply that the treatment of severe liver diseases with liver subcapsular and submesenteric transplantation of HBOs may be clinically effective and safe. These findings provide new insight into HBOs for further experimental and clinical validation.
基金:
Stem Cell and Regenerative Medicine Research Project of the Beijing Science and Technology Commission [Z19110 0001519006]; Innovative Platform Project National Medical Research and Industry-Education Collaboration from State Commission of Development and Reform
第一作者机构:[1]Beijing Univ Chinese Med, Sch Life Sci, Beijing 100029, Peoples R China[2]Beizhong Jingyuan Biotechnol Beijing Ltd, Beijing, Peoples R China
共同第一作者:
通讯作者:
通讯机构:[1]Beijing Univ Chinese Med, Sch Life Sci, Beijing 100029, Peoples R China[5]Sun Yat Sen Univ, Coll Life Sci, State Key Lab Biocontrol, Guangdong Prov Key Lab Pharmaceut Funct Genes, Guangzhou 510006, Guangdong, Peoples R China
推荐引用方式(GB/T 7714):
Li Hongmei,Li Jingyi,Wang Ting,et al.Hepatobiliary organoids differentiated from hiPSCs relieve cholestasis-induced liver fibrosis in nonhuman primates[J].INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES.2024,20(4):1160-1179.doi:10.7150/ijbs.90441.
APA:
Li, Hongmei,Li, Jingyi,Wang, Ting,Sun, Ke,Huang, Guangrui...&Xu, Anlong.(2024).Hepatobiliary organoids differentiated from hiPSCs relieve cholestasis-induced liver fibrosis in nonhuman primates.INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES,20,(4)
MLA:
Li, Hongmei,et al."Hepatobiliary organoids differentiated from hiPSCs relieve cholestasis-induced liver fibrosis in nonhuman primates".INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES 20..4(2024):1160-1179